ArticleFrontiers in immunology2025
Impact of temperature trend-defined seasonality on psoriasis treatment outcomes: a multicenter longitudinal study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of co-exposure to extreme cold and nitrogen dioxide with psoriasis outpatient visits and systemic inflammation.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis severity and symptoms are widely known to vary seasonally. However, evidence on the impact of seasonality on treatment outcomes is limited, with vague season definitions. It also remains unclear whether seasons represent static meteorological levels or dynamic trends. Objective: To assess the impact of a novel temperature trend-defined seasonality on psoriasis treatment responses at 2 and 3 months. Methods: Data were derived from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), a prospective, multicenter registry assessing the effectiveness of biologics (adalimumab, ustekinumab, secukinumab and ixekizumab), conventional systemic therapies (acitretin and methotrexate), and phototherapy. Patients were categorized into warming (consistent temperature increase), transition (non-unidirectional changes), and cooling (consistent temperature decrease) groups based on ambient temperature trends during the treatment period. Effectiveness was defined as achieving Psoriasis Area and Severity Index (PASI) 75 (≥ 75% improvement in PASI), PASI 90 (≥ 90% improvement in PASI), Physician's Global Assessment (PGA) of 0/1, and Dermatology Quality of Life Index minimal important difference (DLQI MID) (≥ 4 points improvement) at 2 and 3 months. Covariate balancing propensity score (CBPS) weighting was applied to balance baseline covariates, and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. Interaction analyses evaluated potential factors that may stratify treatment response. Results: In the 3-month analysis of 1411 patients, the cooling group showed significantly lower odds of achieving PASI 75 (adjusted OR 0.70, 95% CI 0.61-0.80, Conclusions: Cooling trends are associated with reduced treatment efficacy independently of static temperature, humidity, and ultraviolet levels. This BMI-modified effect underscores the importance of personalized management strategies addressing both environmental and patient-specific factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.